Kevin Hicks, PharmD, PhD

My clinical and research efforts focus on the integration of molecular profiling into patient care to guide therapeutic decision making.

Associations

• Pathology
• Health Outcomes & Behavior Program

Education & Training

Graduate:

• University of Michigan, PharmD - Pharmacy
• University of Michigan, PhD - Pharmacology

Fellowship:

• St. Jude Children's Research Hospital - Pharmacogenetics/Precision Medicine

I have two main research interests. The majority of my professional career has focused on understanding how to leverage germline pharmacogenetic test results to improve pharmacotherapy outcomes. I have severed as PI of quality improvement projects and clinical trials investigating clinical benefits of pharmacogenetic driven drug prescribing including for CYP2C19-voriconazole, CYP2C19/CYP2D6-antidepressants, and CYP2D6-pain management. More recently, I have expanded my clinical research interests to include identifying somatic genetic alterations in lung cancer that are predictive of poor clinical outcomes, or associated with acquired resistance, for stratification and individualization of treatment regimens to improve efficacy. These efforts also include researching how to leverage informatics tools to integrate molecular profiling into patient care in a manner that is sustainable and scalable.

• Ho TT, Smith DM, Aquilante CL, Cicali EJ, El Rouby N, Hertz DL, Imanirad I, Patel JN, Scott SA, Swain SM, Tuteja S, Hicks JK. A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice. Clin Pharmacol Ther. 2025 May.117(5):1194-1208. Pubmedid: 39887719. Pmcid: PMC11993294.
• Zhao Y, Amorrortu RP, Hicks JK, Garcia MA, Haura EB, Yin J, Vadaparampil ST, Rollison DE. An examination of factors associated with disparities in clinical trial eligibility guided by the Socioecological Model. Cancer. 2025 Jul.131(13):e35944. Pubmedid: 40530674. Pmcid: PMC12263167.
• Brock PL, Webster M, Liyanarachchi S, Byrne L, Hedges DJ, Gulhati P, Hicks JK, Chan CHF, Onel K, Stout LA, Maxwell W, Pickarski JC, Estrada-Veras J, Salhia B, Axell L, Holman LL, Abdel-Rahman MH, Ringel MD. Germline POT1 Variants in a Pan-Cancer Cohort. JCO Precis Oncol. 2025 Jul.9:e2400946. Pubmedid: 40632976. Pmcid: PMC12243956.
• Cavallari LH, Hicks JK, Patel JN, Elchynski AL, Smith DM, Bargal SA, Fleck A, Aquilante CL, Killam SR, Lemke L, Ochi T, Ramsey LB, Haidar CE, Ho T, El Rouby N, Monte AA, Allen JD, Beitelshees AL, Bishop JR, Bousman C, Campbell R, Cicali EJ, Cook KJ, Duong B, Tsermpini EE, Girdwood ST, Gregornik DB, Grimsrud KN, Lamb N, Lee JC, Lopez RO, Mazhindu TA, Morris SA, Nagy M, Nguyen J, Pasternak AL, Petry N, van Schaik RHN, Schultz A, Skaar TC, Al Alshaykh H, Stevenson JM, Stone RM, Tran NK, Tuteja S, Woodahl EL, Yuan LC, Lee CR. The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation. Pharmacogenet Genomics. 2025 Jan.35(1):1-11. Pubmedid: 39485373. Pmcid: PMC11664750.
• Nassar AH, Kim C, Adeyelu T, Bou Farhat E, Abushukair H, Rakaee M, Matteson K, Lau SF, Takabe Y, Ocejo A, Ardeshir-Larijani F, Leal T, Ramalingam S, Alam S, Gray JE, Hicks J, Kaldas D, Baena J, Berjaga MZ, Nana FA, Grohe C, Leuders H, Citarella F, Cortellini A, Mingo EC, Pancirer D, Das M, Ellis-Caleo TJ, Cheung JM, Lin JJ, Watson AS, Camidge DR, Sridhar A, Parikh K, Crowley F, Marron TU, Aggarwal V, Ahmed M, Sankar K, Kawtharany H, Zhang J, Owen DH, Li M, Nagasaka M, Pinato DJ, Awosika N, Alhamad K, Puri S, Zaman U, Gupta DM, Lau C, Khan H, Liauw J, Velazquez AI, Brown T, Moliner L, Mosteiro M, Rocha P, Evans M, Vanderwalde A, Elliott A, Nieva J, Lopes G, Ma PC, Borghaei H, Lee M, Young L, Aljumaily R, Mirza H, Kwiatkowski DJ, Herbst RS, Flavell RA, Naqash AR, Chiang AC. Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. Nat Commun. 2025 Aug.16(1):7717. Pubmedid: 40830141. Pmcid: PMC12365225.
• Miao R, Blue K, Sommerer K, Shah A, Bottiglieri S, Del Cueto A, Berry DK, Ho TT, Hicks JK, Kim DW. PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience. Cancers (Basel). 2024 Oct.16(20). Pubmedid: 39456541. Pmcid: PMC11505755.
• Nelson RS, Seligson ND, Bottiglieri S, Carballido E, Cueto AD, Imanirad I, Levine R, Parker AS, Swain SM, Tillman EM, Hicks JK. Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566. Cancers (Basel). 2024 Oct.16(21). Pubmedid: 39518158. Pmcid: PMC11544884.
• Hayes TK, Aquilanti E, Persky NS, Yang X, Kim EE, Brenan L, Goodale AB, Alan D, Sharpe T, Shue RE, Westlake L, Golomb L, Silverman BR, Morris MD, Fisher TR, Beyene E, Li YY, Cherniack AD, Piccioni F, Hicks JK, Chi AS, Cahill DP, Dietrich J, Batchelor TT, Root DE, Johannessen CM, Meyerson M. Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. Nat Commun. 2024 Mar.15(1):2742. Pubmedid: 38548752. Pmcid: PMC10978866.
• Tracksdorf T, Smith DM, Pearse S, Cicali EJ, Aquilante CL, Scott SA, Ho TT, Patel JN, Hicks JK, Hertz DL. Strategies for DPYD testing prior to fluoropyrimidine chemotherapy in the US. Support Care Cancer. 2024 Jul.32(8):497. Pubmedid: 38980476.
• Ho TT, Perkins JB, Gonzalez R, Hicks JK, Martinez RA, Duranceau K, North B, Kim J, Teer JK, Yao J, Yoder SJ, Nishihori T, Bejanyan N, Pidala J, Elmariah H. Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients. Pharmacogenomics. 2024 Jan.25(1):29-40. Pubmedid: 38189154.
• Alontaga AY, Cano P, Ozakinci H, Puskas JA, Stewart PA, Welsh EA, Yoder SJ, Hicks JK, Saltos AN, Bossler AD, Haura EB, Koomen JM, Boyle TA. Implementation of a High-Accuracy Targeted Gene Expression Panel for Clinical Care. J Mol Diagn. 2024 Aug.26(8):685-699. Pubmedid: 38777037. Pmcid: PMC11299514.
• Brock P, Liyanarachchi S, Nieminen TT, Chan C, Kohlmann W, Stout LA, Yao S, La Greca A, Jensen KE, Kolesar J, Salhia B, Gulhati P, Hicks JK, Ringel MD. CHEK2 Founder Variants and Thyroid Cancer Risk. Thyroid. 2024 Apr.34(4):477-483. Pubmedid: 38279823. Pmcid: PMC10998703.
• Hayes TK, Aquilanti E, Persky NS, Yang X, Kim EE, Brenan L, Goodale AB, Alan D, Sharpe T, Shue RE, Westlake L, Golomb L, Silverman BR, Morris MD, Fisher TR, Beyene E, Li YY, Cherniack AD, Piccioni F, Hicks JK, Chi AS, Cahill DP, Dietrich J, Batchelor TT, Root DE, Johannessen CM, Meyerson M. Author Correction: Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants. Nat Commun. 2024 Apr.15(1):3273. Pubmedid: 38627431. Pmcid: PMC11021560.
• Hicks JK. Towards UGT1A1 guided irinotecan dosing. Eur J Hum Genet. 2023 Sep.31(9):980-981. Pubmedid: 36750665. Pmcid: PMC10474121.
• Hertz DL, Smith DM, Scott SA, Patel JN, Hicks JK. Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy. Clin Pharmacol Ther. 2023 Oct.114(4):768-779. Pubmedid: 37350752.
• Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM. DPYD Testing: Time to Put Patient Safety First. J Clin Oncol. 2023 May.41(15):2701-2705. Pubmedid: 36821823.
• Singh AM, Rubiera-Pebe R, Ahmad Y, Shafique M, Hicks JK, Tanvetyanon T. Safety Monitoring Activity During EGFR or Anaplastic Lymphoma Kinase Inhibitor Therapy for Patients With Lung Cancer. JCO Oncol Pract. 2023 Jun.19(6):345-351. Pubmedid: 37075260.
• Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023 Jul.13(7):1556-1571. Pubmedid: 37068173.
• Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Ruaño G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023 Jul.114(1):51-68. Pubmedid: 37032427.
• Marin-Acevedo JA, Pellini B, Kimbrough EO, Hicks JK, Chiappori A. Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data. Cancers (Basel). 2023 Jan.15(3). Pubmedid: 36765587. Pmcid: PMC9913773.
• Mosley SA, Cicali E, Del Cueto A, Portman DG, Donovan KA, Gong Y, Langaee T, Gopalan P, Schmit J, Starr JS, Silver N, Chang YD, Rajasekhara S, Smith JE, Soares HP, Clare-Salzler M, Starostik P, George TJ, McLeod HL, Fillingim RB, Hicks JK, Cavallari LH. CYP2D6-guided opioid therapy for adults with cancer pain: A randomized implementation clinical trial. Pharmacotherapy. 2023 Dec.43(12):1286-1296. Pubmedid: 37698371.
• Seligson ND, Kolesar JM, Alam B, Baker L, Lamba JK, Fridley BL, Salahudeen AA, Hertz DL, Hicks JK. Integrating pharmacogenomic testing into paired germline and somatic genomic testing in patients with cancer. Pharmacogenomics. 2023 Aug.24(13):731-738. Pubmedid: 37702060.
• Knepper TC, Boyle TA, Hicks JK, Walko CM. Pharmacist-Driven Precision Medicine: A Ferry to Cross the Chasm of Interpreting Biomarker Testing Reports. JCO Oncol Pract. 2023 Aug.19(8):679-680. Pubmedid: 37335971.
• Tuteja S, Salloum RG, Elchynski AL, Smith DM, Rowe E, Blake KV, Limdi NA, Aquilante CL, Bates J, Beitelshees AL, Cipriani A, Duong BQ, Empey PE, Formea CM, Hicks JK, Mroz P, Oslin D, Pasternak AL, Petry N, Ramsey LB, Schlichte A, Swain SM, Ward KM, Wiisanen K, Skaar TC, Van Driest SL, Cavallari LH, Bishop JR. Multisite evaluation of institutional processes and implementation determinants for pharmacogenetic testing to guide antidepressant therapy. Clin Transl Sci. 2022 Feb.15(2):371-383. Pubmedid: 34562070. Pmcid: PMC8841452.
• Fusco MJ, Knepper TC, Balliu J, Del Cueto A, Laborde JM, Hooda SM, Brohl AS, Bui MM, Hicks JK. Evaluation of Targeted Next-Generation Sequencing for the Management of Patients Diagnosed with a Cancer of Unknown Primary. Oncologist. 2022 Feb.27(1):e9-e17. Pubmedid: 35305098. Pmcid: PMC8842368.
• Robichaux JP, Le X, Vijayan RSK, Hicks JK, Heeke S, Elamin YY, Lin HY, Udagawa H, Skoulidis F, Tran H, Varghese S, He J, Zhang F, Nilsson MB, Hu L, Poteete A, Rinsurongkawong W, Zhang X, Ren C, Liu X, Hong L, Zhang J, Diao L, Madison R, Schrock AB, Saam J, Raymond V, Fang B, Wang J, Ha MJ, Cross JB, Gray JE, Heymach JV. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021 Sep.597(7878):732-737. Pubmedid: 34526717. Pmcid: PMC8481125.
• Levy KD, Blake K, Fletcher-Hoppe C, Franciosi J, Goto D, Hicks JK, Holmes AM, Kanuri SH, Madden EB, Musty MD, Orlando L, Pratt VM, Ramos M, Wu R, Ginsburg GS. Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. Genet Med. 2021 Oct.23(10):2020. Pubmedid: 33288881. Pmcid: PMC8486650.
• McDonald J, Chuang CY, Hicks JK, Berry DK, Imanirad I, Rishi A, Frakes JM, Hoffe SE, Felder S. FANCD2 Mutation in a Patient With Early Rectal Cancer Receiving Definitive Chemoradiation. Adv Radiat Oncol. 2021 May.6(5):100717. Pubmedid: 34258475. Pmcid: PMC8260782.
• Hicks JK, Howard R, Reisman P, Adashek JJ, Fields KK, Gray JE, McIver B, McKee K, O'Leary MF, Perkins RM, Robinson E, Tandon A, Teer JK, Markowitz J, Rollison DE. Integrating Somatic and Germline Next-Generation Sequencing Into Routine Clinical Oncology Practice. JCO Precis Oncol. 2021 May.5. Pubmedid: 34095711. Pmcid: PMC8169076.
• Shields MD, Hicks JK, Boyle TA, Haura EB, Creelan BC. Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib. J Thorac Oncol. 2021 Mar.16(3):e15-e17. Pubmedid: 33641722.
• Nelson RS, Seligson ND, Bottiglieri S, Carballido E, Cueto AD, Imanirad I, Levine R, Parker AS, Swain SM, Tillman EM, Hicks JK. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers (Basel). 2021 Mar.13(7). Pubmedid: 33805415. Pmcid: PMC8036652.
• Ramsey LB, Namerow LB, Bishop JR, Hicks JK, Bousman C, Croarkin PE, Mathews CA, Van Driest SL, Strawn JR. Thoughtful Clinical Use of Pharmacogenetics in Child and Adolescent Psychopharmacology. J Am Acad Child Adolesc Psychiatry. 2021 Jun.60(6):660-664. Pubmedid: 32860906. Pmcid: PMC8141104.
• Rubiera-Pebe R, Hicks JK, Tanvetyanon T. Efficacy of tyrosine kinase inhibitors against lung cancer with EGFR exon 18 deletion: Case report and pooled analysis. Cancer Treat Res Commun. 2021 Jun.28:100407. Pubmedid: 34090219.
• Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey LB, Shi Y, Tang LA, Aquilante CL, Beitelshees AL, Blake KV, Cimino JJ, Davis BH, Empey PE, Kao DP, Lemkin DL, Limdi NA, Lipori GP, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley LK, Williams H, Winterstein AG, Van Driest SL, Cavallari LH, Peterson JF. Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems. Clin Pharmacol Ther. 2021 Jul.110(1):179-188. Pubmedid: 33428770. Pmcid: PMC8217370.
• Fusco MJ, Saeed-Vafa D, Carballido EM, Boyle TA, Malafa M, Blue KL, Teer JK, Walko CM, McLeod HL, Hicks JK, Extermann M, Fleming JB, Knepper TC, Kim DW. Identification of Targetable Gene Fusions and Structural Rearrangements to Foster Precision Medicine in KRAS Wild-Type Pancreatic Cancer. JCO Precis Oncol. 2021 Jan.5. Pubmedid: 34250383. Pmcid: PMC8232071.
• Duarte JD, Dalton R, Elchynski AL, Smith DM, Cicali EJ, Lee JC, Duong BQ, Petry NJ, Aquilante CL, Beitelshees AL, Empey PE, Johnson JA, Obeng AO, Pasternak AL, Pratt VM, Ramsey LB, Tuteja S, Van Driest SL, Wiisanen K, Hicks JK, Cavallari LH. Multisite investigation of strategies for the clinical implementation of pre-emptive pharmacogenetic testing. Genet Med. 2021 Dec.23(12):2335-2341. Pubmedid: 34282303. Pmcid: PMC8633054.
• Haura EB, Hicks JK, Boyle TA. Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib. J Thorac Oncol. 2020 Sep.15(9):e154-e156. Pubmedid: 32854916.
• Levy KD, Blake K, Fletcher-Hoppe C, Franciosi J, Goto D, Hicks JK, Holmes AM, Kanuri SH, Madden EB, Musty MD, Orlando L, Pratt VM, Ramos M, Wu R, Ginsburg GS. Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. Genet Med. 2020 Oct.22(10):1730. Pubmedid: 32719393. Pmcid: PMC7521989.
• Berry DK, Wang X, Michalski ST, Kang HC, Yang S, Creelan BC, McLeod HL, Hicks JK. Clinical Cohort Analysis of Germline EGFR T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages. JCO Precis Oncol. 2020 Mar.4. Pubmedid: 34164592. Pmcid: PMC8216676.
• Hicks JK, Quilitz RE, Komrokji RS, Kubal TE, Lancet JE, Pasikhova Y, Qin D, So W, Caceres G, Kelly K, Salchert YS, Shahbazian K, Abbas-Aghababazadeh F, Fridley BL, Velez AP, McLeod HL, Greene JN. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations. Clin Pharmacol Ther. 2020 Mar.107(3):563-570. Pubmedid: 31549389. Pmcid: PMC7018540.
• Dexter P, Ong H, Elsey A, Bell G, Walton N, Chung W, Rasmussen L, Hicks K, Owusu-Obeng A, Scott S, Ellis S, Peterson J. Development of a Genomic Data Flow Framework: Results of a Survey Administered to NIH-NHGRI IGNITE and eMERGE Consortia Participants. Amia Annu Symp Proc. 2020 Mar.2019:363-370. Pubmedid: 32308829. Pmcid: PMC7153090.
• Duong BQ, Arwood MJ, Hicks JK, Beitelshees AL, Franchi F, Houder JT, Limdi NA, Cook KJ, Owusu Obeng A, Petry N, Tuteja S, Elsey AR, Cavallari LH, Wiisanen K. Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network. Pharmgenomics Pers Med. 2020 Jul.13:217-226. Pubmedid: 32765043. Pmcid: PMC7373415.
• Hicks JK, Bishop JR, Gammal RS, Sangkuhl K, Bousman CA, Leeder JS, Llerena A, Mueller DJ, Ramsey LB, Scott SA, Skaar TC, Caudle KE, Klein TE, Gaedigk A. A Call for Clear and Consistent Communications Regarding the Role of Pharmacogenetics in Antidepressant Pharmacotherapy. Clin Pharmacol Ther. 2020 Jan.107(1):50-52. Pubmedid: 31664715. Pmcid: PMC6925627.
• Huddart R, Hicks JK, Ramsey LB, Strawn JR, Smith DM, Bobonis Babilonia M, Altman RB, Klein TE. PharmGKB summary: sertraline pathway, pharmacokinetics. Pharmacogenet Genomics. 2020 Feb.30(2):26-33. Pubmedid: 31851125. Pmcid: PMC7008964.
• Hockings JK, Pasternak AL, Erwin AL, Mason NT, Eng C, Hicks JK. Pharmacogenomics: An evolving clinical tool for precision medicine. Cleve Clin J Med. 2020 Feb.87(2):91-99. Pubmedid: 32015062.
• Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL. Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients. JAMA Netw Open. 2020 Dec.3(12):e2029411. Pubmedid: 33315113. Pmcid: PMC7737091.
• Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Obeng AO, Beitelshees AL, Bell GC, Blake K, Crona DJ, Dressler L, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, Johnson JA, Peterson JF, Empey PE, Skaar TC. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med. 2019 Oct.21(10):2255-2263. Pubmedid: 30894703. Pmcid: PMC6754805.
• Levy KD, Blake K, Fletcher-Hoppe C, Franciosi J, Goto D, Hicks JK, Holmes AM, Kanuri SH, Madden EB, Musty MD, Orlando L, Pratt VM, Ramos M, Wu R, Ginsburg GS. Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. Genet Med. 2019 Mar.21(3):743-747. Pubmedid: 29997387. Pmcid: PMC6330142.
• Hicks JK, Aquilante CL, Dunnenberger HM, Gammal RS, Funk RS, Aitken SL, Bright DR, Coons JC, Dotson KM, Elder CT, Groff LT, Lee JC. Precision Pharmacotherapy: Integrating Pharmacogenomics into Clinical Pharmacy Practice. J Am Coll Clin Pharm. 2019 Jun.2(3):303-313. Pubmedid: 32984775. Pmcid: PMC7516785.
• Levy KD, Blake K, Fletcher-Hoppe C, Franciosi J, Goto D, Hicks JK, Holmes AM, Kanuri SH, Madden EB, Musty MD, Orlando L, Pratt VM, Ramos M, Wu R, Ginsburg GS. Correction: Opportunities to implement a sustainable genomic medicine program: lessons learned from the IGNITE Network. Genet Med. 2019 Jul.21(7):1670. Pubmedid: 30158693. Pmcid: PMC6752260.
• Hicks JK, McLeod HL. Probabilistic medicine: a pre-emptive approach is needed for cancer therapeutic risk mitigation. Biomark Med. 2019 Aug.13(12):987-990. Pubmedid: 31385527.
• Hicks JK, Henderson-Jackson E, Duggan J, Joyce DM, Brohl AS. Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma. Diagn Pathol. 2018 Oct.13(1):77. Pubmedid: 30314519. Pmcid: PMC6186031.
• Goldberg ME, Montesion M, Young L, Suh J, Greenbowe J, Kennedy M, Giaccone G, Akerley WL, Dowlati A, Creelan BC, Hicks JK, Hesketh PJ, Kelly KL, Riess JW, Miller VA, Stephens PJ, Frampton GM, Ali S, Gregg JP, Albacker LA. Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC. PLoS One. 2018 Nov.13(11):e0208097. Pubmedid: 30481207. Pmcid: PMC6258560.
• Vela CM, Van den Bergh M, Gillis NK, Ball M, Hussaini MO, Walko CM, Hicks JK, Perez L, Padron E, Komrokji RS. Somatic Sequencing Identifies Trametinib-Responsive Myelodysplastic Syndrome and Finds Acquired Clonal Hematopoiesis of Indeterminate Potential. JCO Precis Oncol. 2018 Nov.2. Pubmedid: 35135101. Pmcid: PMC9797240.
• Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ, McLeod HL, Cavallari LH. Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial. Contemp Clin Trials. 2018 May.68:7-13. Pubmedid: 29535047. Pmcid: PMC5899651.
• Hicks JK, Shealy A, Schreiber A, Coleridge M, Noss R, Natowicz M, Moran R, Moss T, Erwin A, Eng C. Patient Decisions to Receive Secondary Pharmacogenomic Findings and Development of a Multidisciplinary Practice Model to Integrate Results Into Patient Care. Clin Transl Sci. 2018 Jan.11(1):71-76. Pubmedid: 28749586. Pmcid: PMC5759733.
• Le X, Puri S, Negrao MV, Nilsson M, Robichaux JP, Boyle TA, Hicks JK, Lovinger K, Roarty EB, Rinsurongkawong W, Tang M, Sun H, Elamin YY, Lacerda L, Lewis J, Lee JJ, Roth JA, Swisher SG, Zhang J, William WN, Glisson BS, Papadimitrakopoulou VA, Gray JE, Heymach JV. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res. 2018 Dec.24(24):6195-6203. Pubmedid: 30228210. Pmcid: PMC6295279.
• Hicks JK, Boyle T, Albacker LA, Madison R, Frampton G, Creelan BC. Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion. J Thorac Oncol. 2018 Aug.13(8):e148-e150. Pubmedid: 30049378.
• Vela CM, Knepper TC, Gillis NK, Walko CM, McLeod HL, Hicks JK. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use. Pharmacotherapy. 2017 Sep.37(9):1043-1051. Pubmedid: 28235141.
• Hicks JK, Saller J, Wang E, Boyle T, Gray JE. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results. Lung Cancer. 2017 Sep.111:135-138. Pubmedid: 28838384.
• Vo TT, Bell GC, Owusu Obeng A, Hicks JK, Dunnenberger HM. Pharmacogenomics Implementation: Considerations for Selecting a Reference Laboratory. Pharmacotherapy. 2017 Sep.37(9):1014-1022. Pubmedid: 28699700.
• Gillis NK, Hicks JK, Bell GC, Daly AJ, Kanetsky PA, McLeod HL. Incidence and Triggers of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Large Cancer Patient Cohort. J Invest Dermatol. 2017 Sep.137(9):2021-2023. Pubmedid: 28549953.
• Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA. The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. Clin Transl Sci. 2017 May.10(3):143-146. Pubmedid: 28294551. Pmcid: PMC5421730.
• Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 Jul.102(1):37-44. Pubmedid: 27997040. Pmcid: PMC5478479.
• Knepper TC, Bell GC, Hicks JK, Padron E, Teer JK, Vo TT, Gillis NK, Mason NT, McLeod HL, Walko CM. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. Oncologist. 2017 Feb.22(2):144-151. Pubmedid: 28179575. Pmcid: PMC5330702.
• Hicks JK, Dunnenberger HM, Gumpper KF, Haidar CE, Hoffman JM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm. 2016 Dec.73(23):1967-1976. Pubmedid: 27864204. Pmcid: PMC5117634.
• Ladd B, Ackroyd JJ, Hicks JK, Canman CE, Flanagan SA, Shewach DS. Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity. DNA Repair (Amst). 2013 Dec.12(12):1114-1121. Pubmedid: 24231389. Pmcid: PMC3922048.
• Hicks JK, Chute CL, Paulsen MT, Ragland RL, Howlett NG, Guéranger Q, Glover TW, Canman CE. Differential roles for DNA polymerases eta, zeta, and REV1 in lesion bypass of intrastrand versus interstrand DNA cross-links. Mol Cell Biol. 2010 Mar.30(5):1217-1230. Pubmedid: 20028736. Pmcid: PMC2820889.

• Title: Evaluation of a Quality Improvement Initiative to Increase Biomarker Testing in Early-Stage NSCLC Coupled with Precision Medicine Services to Support Biomarker-Driver Therapy and Clinical Trials
  Award Number: A-40351
  Sponsor: Lilly USA, LLC
  Hicks, J. (PD/PI)